Within the context of prostate cancer, the PI3K–Akt–mammalian target of rapamycin (mTOR) pathway is one of the most frequently activated pathways, with genomic alterations occurring in approximately 50% of patients with prostate cancer [3]. This evidence concerns the gene MTOR and prostate cancer.